Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase

[1]  K. Brøsen,et al.  Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine , 2004, European Journal of Clinical Pharmacology.

[2]  W. Kalow.  Genetic variation in the human hepatic cytochrome P-450 system , 2004, European Journal of Clinical Pharmacology.

[3]  T. Leemann,et al.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers , 2004, European Journal of Clinical Pharmacology.

[4]  K. Brøsen,et al.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.

[5]  K. Brøsen.  Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics , 1990, Clinical pharmacokinetics.

[6]  K. Brøsen,et al.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. , 1990, British journal of clinical pharmacology.

[7]  B. Angelin,et al.  Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine , 1990, Clinical pharmacology and therapeutics.

[8]  D. Roden,et al.  Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. , 1989, The Journal of pharmacology and experimental therapeutics.

[9]  K. Midha,et al.  Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  R. Dahlqvist,et al.  Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.

[11]  K. Midha,et al.  Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. , 1987, Journal of pharmaceutical sciences.

[12]  A. Boobis,et al.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. , 1986, British journal of clinical pharmacology.

[13]  D. Notterman,et al.  Stereoselective renal tubular secretion of quinidine and quinine , 1986, Clinical pharmacology and therapeutics.

[14]  T. Inaba,et al.  Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. , 1986, British journal of clinical pharmacology.

[15]  S. Otton,et al.  Sparteine oxidation is practically abolished in quinidine-treated patients. , 1986, British journal of clinical pharmacology.

[16]  G McKay,et al.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[17]  T. Henthorn,et al.  Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.

[18]  W. Kalow,et al.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[19]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[20]  K. Midha,et al.  Identification of new secondary metabolites of methoxyphenamine in man. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.